Alex Thompson
Stock Analyst at Stifel
(3.84)
# 676
Out of 5,113 analysts
41
Total ratings
63.64%
Success rate
7.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $233.65 | +9.57% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $833.16 | +49.79% | 5 | Dec 11, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $80 → $56 | $47.12 | +18.85% | 2 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $51.21 | +26.93% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $29.94 | -16.50% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $11.97 | +83.79% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $71.06 | -22.60% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $15.65 | +130.03% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $52.52 | +14.24% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $34.14 | +43.53% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $32.29 | +67.23% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $13.97 | -85.68% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $15.91 | +333.69% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $3.82 | -73.82% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $33.06 | +20.99% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $57.62 | +455.36% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $26.60 | +27.82% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.29 | +2,458.14% | 1 | Dec 14, 2022 |
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $233.65
Upside: +9.57%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $833.16
Upside: +49.79%
AnaptysBio
Dec 11, 2025
Maintains: Buy
Price Target: $80 → $56
Current: $47.12
Upside: +18.85%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $51.21
Upside: +26.93%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $29.94
Upside: -16.50%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $11.97
Upside: +83.79%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $71.06
Upside: -22.60%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $15.65
Upside: +130.03%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $52.52
Upside: +14.24%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $34.14
Upside: +43.53%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $32.29
Upside: +67.23%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $13.97
Upside: -85.68%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $15.91
Upside: +333.69%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.82
Upside: -73.82%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $33.06
Upside: +20.99%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $57.62
Upside: +455.36%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $26.60
Upside: +27.82%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.29
Upside: +2,458.14%